Posted by Michael Wonder on 25 Mar 2021
CStone announces new drug approval of Gavreto (pralsetinib) as first selective RET inhibitor in China, providing a new therapy for a subset of non-small cell lung cancer patients
24 March 2021 - Gavreto is the first approved selective RET inhibitor in China and first approved precision therapy for CStone.
CStone Pharmaceuticals today announces that the National Medical Products Administration of China has approved Gavreto (pralsetinib) capsules for the treatment of adult patients with locally advanced or metastatic rearranged during transfection fusion-positive non-small cell lung cancer after platinum-based chemotherapy.
